Laffi G, Foschi M, Masini E, Simoni A, Mugnai L, La Villa G, Barletta G, Mannaioni P F, Gentilini P
Istituto di Medicina Interna, University of Florence, School of Medicine, Italy.
Hepatology. 1995 Dec;22(6):1666-73.
An increased release of nitric oxide (NO), a powerful vasodilating agent, has been proposed to play a role in the pathogenesis of vasodilation and hyperdynamic circulation associated with advanced cirrhosis. We evaluated NO synthase (NOS) activity in peripheral leukocytes of 12 cirrhotic patients and 9 healthy subjects together with plasma endotoxin levels and systemic hemodynamic (by a noninvasive echocardiographic method). NOS activity was evaluated by (1) measuring the capacity of isolated polymorphonuclear cells (PMNs) and monocytes to convert [3H]arginine to [3H]citrulline; (2) measuring the ability of neutrophils and monocytes to inhibit thrombin-induced platelet aggregation and to increase guanosine 3'-5'-cyclic monophosphate content in coincubated platelets, an expression of NO release from these cells. Both neutrophils and monocytes from cirrhotic patients produced significantly higher amounts of [3H]citrulline than cells obtained from healthy subjects (P < .001 and P < .02 for neutrophils and monocytes, respectively) and were more effective than control cells in inhibiting platelet aggregation (P < .05 and P < .001, respectively for 2 x 10(6) cells) and in increasing guanosine 3'-5'-cyclic monophosphate content in coincubated platelets (P < .05 and P < .001, respectively). The anti-aggregating activity expressed by leukocytes has a pharmacological profile similar to that described for NO, because it increased after addition of superoxide dismutase, a superoxide anion scavenger, and markedly decreased after inhibition of nitric oxide synthesis with NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine-methyl ester (L-NAME). Cirrhotic patients had significantly higher plasma endotoxin levels (P < .001) and cardiac index (P < .01) when compared with controls.(ABSTRACT TRUNCATED AT 250 WORDS)
一氧化氮(NO)是一种强效血管舒张剂,其释放增加被认为在晚期肝硬化相关的血管舒张和高动力循环的发病机制中起作用。我们评估了12例肝硬化患者和9名健康受试者外周血白细胞中的一氧化氮合酶(NOS)活性,同时检测了血浆内毒素水平和全身血流动力学(采用无创超声心动图方法)。通过以下方法评估NOS活性:(1)测量分离的多形核细胞(PMN)和单核细胞将[3H]精氨酸转化为[3H]瓜氨酸的能力;(2)测量中性粒细胞和单核细胞抑制凝血酶诱导的血小板聚集以及增加共孵育血小板中鸟苷3'-5'-环磷酸含量的能力,这是这些细胞释放NO的一种表现。肝硬化患者的中性粒细胞和单核细胞产生的[3H]瓜氨酸量均显著高于健康受试者的细胞(中性粒细胞和单核细胞分别为P <.001和P <.02),并且在抑制血小板聚集方面比对照细胞更有效(2×10(6)个细胞时分别为P <.05和P <.001),在增加共孵育血小板中鸟苷3'-5'-环磷酸含量方面也更有效(分别为P <.05和P <.001)。白细胞表现出的抗聚集活性具有与NO相似的药理学特征,因为在添加超氧化物歧化酶(一种超氧化物阴离子清除剂)后其活性增加,而在用NG-单甲基-L-精氨酸(L-NMMA)和NG-硝基-L-精氨酸甲酯(L-NAME)抑制一氧化氮合成后显著降低。与对照组相比,肝硬化患者的血浆内毒素水平显著更高(P <.001),心脏指数也显著更高(P <.01)。(摘要截短于250字)